Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 1.00 |
| ▸ | PNMT | P11086 | 5/20 | 0.85 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1017313 | 0.98 | ASIC3 (0.96) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL29473102 | 0.92 | PNMT (1.00) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL552932 | 0.92 | PNMT (1.00) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL1266299 | 0.90 | PNMT (0.96) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL29528420 | 0.90 | PNMT (0.96) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL29758914 | 0.88 | ASIC3 (0.79) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL1264714 | 0.88 | ASIC3 (0.79) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL1264341 | 0.87 | PNMT (0.77) | ASIC3PNMTDRD2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL21753254 | 0.86 | ASIC3 (0.76) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL21753269 | 0.85 | PNMT (0.74) | ASIC3PNMTDRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638623-A | Synthesis process of 6-bromo-1, 2,3, 4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-115894363-B | Synthesis process of 6-bromo-1, 2,3, 4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-115894363-A | Synthesis process of 6-bromo-1,2,3,4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | claimed |
| CN-109943861-B | Method for synthesizing alpha-phosphoramidate by electrochemical oxidation | 南京大学 | 2020-11-27 | — | — | CN | claimed |
| CN-111621805-A | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2020-09-04 | — | — | CN | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1045843-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1045843-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5977134-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999028313-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | ASIC3 2202/4885PNMT 3109/4885DRD2 2749/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | ASIC3 4164/4885PNMT 998/4885DRD2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.